A Substantial Market/Medical Opportunity

Conventional drug development is an exceedingly high-cost, high-risk venture. On average, a new drug requires 10 years and $1 billion to advance from bench to bedside with a clinical trial failure rate of approximately 90%. Approximately $20 billion is spent annually on drug development that ends in failure.

Heart and brain toxicity are the two leading causes of toxicology-related drug failures in clinical studies, a result of the inferior animal models used in preclinical testing.  microHeart^® and microBrain^®, the world’s first ready-to-use assay plates containing heart and brain microtissues, are designed to address this significant market opportunity by offering better prediction in drug toxicity and efficacy tests because they more naturally reflect human heart and brain physiology.

Further, StemoniX’s high-volume manufacturing processes, which can produce more than one billion cells per batch, are able to achieve economies of scale that allow pharmaceutical companies to screen drug candidates on human cells rapidly, accurately, and affordable.